GENE ONLINE|News &
Opinion
Blog

2022-11-01| COVID-19

AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union

by Max Heirich
Share To

The European Medicines Agency (EMA) granted full Marketing Authorization to Astrazeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), in the European Union on November 1. Though having previously received conditional marketing authorization, the full authorization comes after a positive opinion given by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

Related Article: Pfizer to Raise COVID-19 Vaccine Prices Amidst Rising Flu Cases

Finally Granted Full Authorization in the European Union

Invented by the University of Oxford, Vaxzevria is AstraZeneca’s COVID-19 vaccine. Unlike the more commonly used mRNA vaccines, like Pfizer’s or Moderna’s, Vaxzevria uses a weakened version of a common cold virus and the genetic material of the SARS-CoV-2 virus spike protein for immunization. 

Though AstraZeneca’s vaccine was a contemporary of Pfizer’s and Moderna’s early on in the pandemic, manufacturing issues and safety concerns over rare blood clots saw the vaccine lose momentum for the company. For a time, the company shifted its focus away from its vaccine to instead create treatments for the novel virus, like Evusheld

However, on November 1, the EMA granted AstraZeneca vaccine full Marketing Authorization. Due to the urgency of the COVID-19 pandemic, the agency previously only granted conditional authorization. This full approval is based on the CHMP’s positive opinion after their review of clinical studies and real-world evidence. 

This data showed that the three-shot series provides equally effective protection against hospitalization and death from COVID-19. The CHMP also found that Vaxzevria provided adequate defense against all forms of COVID-19.

On the approval, Iskra Reic, Executive Vice President, Vaccines and Immune Therapies at AstraZeneca, said, “The move from conditional to full marketing authorization for Vaxzevria is an important confirmation by the EMA of the safety and efficacy of Vaxzevria, demonstrating that the benefits continue to outweigh the potential risks.”

Since Vaxzevria’s rollout, AstraZeneca estimates that its vaccine helped save more than six million lives worldwide through the over three billion doses administered in over one hundred and eighty countries. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
AstraZeneca Invests $26.5 Million in New Production Line for Diabetes Drug in China
2024-01-19
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top